Where to buy Tazemetostat

Tazemetostat is indicated for the treatment of adults and children aged 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not candidates for complete resection. Tazerestat is also indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are IZH2 mutation-positive and who have received at least 2 prior systemic therapies. Tazerestat is also indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options.

Tazerestat is a new EZH2 inhibitor that has been shown to be effective, safe and with tolerable side effects in clinical trials. However, tazerestat is just the beginning of targeting epigenetic regulators. EZH2 has been shown to be involved in oncological processes in many other solid tumors and lymphomas. Other EZH2 inhibitors currently in clinical trials with tazerestat are being studied in DLBCL, mantle cell lymphoma, prostate cancer, mesothelioma, urothelial carcinoma and rhabdoid tumors. EZH2 inhibitors may even have potential synergistic effects when combined with immunotherapy or conventional chemotherapy.

The original drug of tazerestat is not yet available in the domestic market, so it is not included in medical insurance. Domestic patients cannot yet purchase this drug. Tazerestat US version of the original drug, specification200mg*240 tablets, which is marketed overseas, may cost around 200,000 yuan per bottle (the price may fluctuate due to exchange rates), which is very expensive. At present, there are no generic drugs of tazerestat produced and launched. For more drug information and specific prices, please consult the medical consultant of the drug.